三氧化二砷介入治疗中晚期原发性肝癌临床疗效研究.doc

三氧化二砷介入治疗中晚期原发性肝癌的临床疗效研究 　　【摘要】 目的：探讨三氧化二砷（As2O3）介入治疗中晚期原发性肝癌临床效果、不良反应及安全性。方法：选取2013年3月-2015年2月本院收治的肝癌患者156例作为研究对象，采用随机数字表法将其分成两组，每组78例，均给予介入治疗。观察组治疗方案为As2O3 20 mg，丝裂霉素10 mg，洛铂50 mg，超液态碘油10 mL；对照组治疗方案为表阿霉素（表柔吡星）40 mg/m2，丝裂霉素10 mg，洛铂50 mg，超液态碘油10 mL。比较两组临床效果、不良反应发生情况及生活质量。结果：观察组总有效率高于对照组，比较差异有统计学意义（P0.05）；治疗中主要出现的不良反应为骨髓抑制、恶心呕吐、疼痛、发热、肝功能损伤等，采取相应措施后可有效缓解，且两组均无Ⅳ度不良反应，也无治疗相关死亡发生。治疗后生活质量改善情况观察组更明显。结论：As2O3介入治疗中晚期原发性肝癌时能明显提高治疗的总有效率，改善患者生活质量，不良反应较轻，是肝癌介入治疗用药的较佳选择，值得临床推广。 　　【关键词】 原发性肝癌； 介入治疗； 三氧化二砷； 临床疗效； 安全性 　　【Abstract】 Objective：To study the clinical effects，adverse reactions and safety of Arsenic Trioxide in interventional treatment of advanced primary liver cancer. Method：156 patients with primary liver cancer in our hospital from March 2013 to February 2015 were selected and randomly divided into two groups，each group had 78 cases.All patients received the interventional treatment.The observation group was treated with Arsenic Trioxide 20 mg，Mitomycin 10 mg，Lobapatin 50 mg and UFL 10 mL.The control group was treated with Epirubicin 40 mg/m2，Mitomycin 10 mg，Lobapatin 50 mg and UFL 10 mL.The treatment effect，adverse reactions and living quality of the two groups were compared.Result：The total effective rate of the observation group was higher than that of the control group，the difference was statistically significant（P0.05）.During treatment，the major adverse reactions were bone marrow suppression，nausea and vomiting，pain，fever，hepatic injury and so on. The symptoms were effectively relieved after taking measures.There were neither Ⅳ degree toxic response nor death related to the treatment.After treatment，the improvement of quality of life in the observation group was more obvious.Conclusion： The interventional treatment of Arsenic Trioxide in advanced primary liver cancer can improve the total efficiency，promote patients’ quality of life and has fewer adverse reactions. Arsenic Trioxide is a better choice for hepatocarcinoma interventional therapy，which is worthy of